Genocea Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of T-cell immunotherapies for infectious diseases and cancer. Headquartered in Massachusetts, Genocea leverages its proprietary ATLAS™ antigen identification platform to pinpoint the specific proteins that drive protective T-cell responses. By mapping the immune system’s recognition patterns, the company aims to create targeted therapeutic vaccines that stimulate robust and durable immunity.
The company’s product pipeline has included GEN-003, a therapeutic vaccine candidate for genital herpes that advanced into Phase II clinical trials, demonstrating reductions in viral shedding and lesion rates. In response to the global pandemic, Genocea also initiated the development of AdCOVID, an intranasal vaccine candidate for COVID-19. More recently, the company has pivoted toward oncology, applying its ATLAS platform to identify tumor-specific antigens and develop personalized immunotherapies intended to enhance anti-tumor T-cell activity.
Founded in 2011 as a spinout from research at the Massachusetts Institute of Technology, Genocea has built a management team with deep expertise in virology, immunology and translational medicine. The leadership group includes seasoned executives in vaccine development and clinical operations, supported by a scientific advisory board of industry and academic experts. Over the years, Genocea has forged collaborations with leading research institutions and forged strategic partnerships to advance its pipeline.
Genocea conducts its research and clinical trials across North America and Europe, with a focus on expanding its antigen discovery platform to address emerging pathogens and diverse cancer types. The company’s long‐term strategy centers on leveraging its high‐throughput, data-driven approach to accelerate candidate selection and improve the likelihood of clinical success, positioning Genocea as an innovator in the field of T-cell–driven vaccine and immunotherapy development.
AI Generated. May Contain Errors.
Free GNCAQ Stock Alerts